InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee CJ, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024 Mar 15. PMID: 38488813.
      Citations:    Fields:    
    2. Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O'Neill E, Porter LH, Ranasinghe W, Sunada T, Williams ED, Butler LM, Corey E, van Weerden WM, Taylor RA, Risbridger GP, Lawrence MG. Defining the challenges and opportunities for using patient-derived models in prostate cancer research. Prostate. 2024 May; 84(7):623-635. PMID: 38450798; PMCID: PMC11014775.
      Citations:    Fields:    
    3. Paindelli C, Parietti V, Barrios S, Shepherd P, Pan T, Wang WL, Satcher RL, Logothetis CJ, Navone N, Campbell MT, Mikos AG, Dondossola E. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater. 2024 Apr 01; 178:83-92. PMID: 38387748.
      Citations:    Fields:    
    4. Habowski AN, Budagavi DP, Scherer SD, Aurora AB, Caligiuri G, Flynn WF, Langer EM, Brody JR, Sears RC, Foggetti G, Arnal Estape A, Nguyen DX, Politi KA, Shen X, Hsu DS, Peehl DM, Kurhanewicz J, Sriram R, Suarez M, Xiao S, Du Y, Li XN, Navone NM, Labanca E, Willey CD. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations. Cancers (Basel). 2024 Jan 29; 16(3). PMID: 38339316; PMCID: PMC10854945.
    5. Rather HA, Almousa S, Kumar A, Sharma M, Pennington I, Kim S, Su Y, He Y, Ghara AR, Sai KKS, Navone NM, Vander Griend DJ, Deep G. The ?-Secretase 1 Enzyme as a Novel Therapeutic Target for Prostate Cancer. Cancers (Basel). 2023 Dec 19; 16(1). PMID: 38201438; PMCID: PMC10778021.
    6. Charles C, Lloyd SM, Piyarathna DWB, Gohlke J, Rasaily U, Putluri V, Simons BW, Zaslavsky A, Nallandhighal S, Michailidis G, Palanisamy N, Navone N, Jones JA, Ittmann MM, Putluri N, Rowley DR, Salami SS, Palapattu GS, Sreekumar A. Role of adenosine deaminase in prostate cancer progression. Am J Clin Exp Urol. 2023; 11(6):594-612. PMID: 38148936; PMCID: PMC10749386.
    7. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543. PMID: 37930121; PMCID: PMC10718063.
      Citations:    Translation:HumansAnimalsCells
    8. Giafaglione JM, Crowell PD, Delcourt AML, Hashimoto T, Ha SM, Atmakuri A, Nunley NM, Dang RMA, Tian M, Diaz JA, Tika E, Payne MC, Burkhart DL, Li D, Navone NM, Corey E, Nelson PS, Lin NYC, Blanpain C, Ellis L, Boutros PC, Goldstein AS. Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol. 2023 Dec; 25(12):1821-1832. PMID: 38049604; PMCID: PMC10709144.
      Citations: 2     Fields:    Translation:HumansCells
    9. Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, Ye H, Zoubeidi A, Christofk HR, Rettig MB, Reiter RE, Haffner MC, Boutros PC, Shirihai OS, Divakaruni AS, Goldstein AS. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 10 31; 42(10):113221. PMID: 37815914.
      Citations:    Fields:    Translation:HumansCells
    10. Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, Moore AR, Wong EWP, Pachai MR, Xie Y, Sher J, Zhao JL, Khudoynazarova M, Gopalan A, Chan J, Khurana E, Shepherd P, Navone NM, Chi P, Chen Y. ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer. Sci Adv. 2023 04 05; 9(14):eadc9446. PMID: 37018402; PMCID: PMC10075989.
      Citations:    Fields:    Translation:HumansAnimals
    11. Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. The future of patient-derived xenografts in prostate cancer research. Nat Rev Urol. 2023 06; 20(6):371-384. PMID: 36650259; PMCID: PMC10789487.
      Citations: 1     Fields:    Translation:HumansAnimals
    12. Sablatura LK, Bircsak KM, Shepherd P, Bathina M, Queiroz K, Farach-Carson MC, Kittles RA, Constantinou PE, Saleh A, Navone NM, Harrington DA. A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts. Adv Healthc Mater. 2023 06; 12(14):e2201434. PMID: 36461624; PMCID: PMC10235208.
      Citations:    Fields:    Translation:HumansAnimals
    13. Toro A, Lage-Vickers S, Bizzotto J, Vilicich F, Sabater A, Pascual G, Ledesma-Bazan S, Sanchis P, Ruiz MS, Arevalo AP, Porfido JL, Abbate M, Seniuk R, Labanca E, Anselmino N, Navone NM, Alonso DF, Vazquez E, Crispo M, Cotignola J, Gueron G. Pin-Pointing the Key Hubs in the IFN-? Pathway Responding to SARS-CoV-2 Infection. Viruses. 2022 09 30; 14(10). PMID: 36298734; PMCID: PMC9610092.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    14. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758. PMID: 36100698.
    15. Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM, Laberiano Fern?ndez C. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel). 2022 Jun 30; 14(13). PMID: 35805010; PMCID: PMC9265062.
    16. Anselmino N, Labanca E, Shepherd PDA, Mitrofanova A, Navone N, Sanchis P, Lage-Vickers S, Sabater A, Lavignolle R, Bizzotto J, Toro A, Valacco MP, Vazquez E, Cotignola J, Gueron G. Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer Cells. Cancers (Basel). 2022 Apr 21; 14(9). PMID: 35565211; PMCID: PMC9104818.
    17. Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 04 05; 39(1):110595. PMID: 35385726; PMCID: PMC9414743.
      Citations:    Fields:    Translation:HumansAnimalsCells
    18. Anselmino N, Labanca E, Navone N, Lage-Vickers S, Sanchis P, Bizzotto J, Toro A, Sabater A, Lavignolle R, Paez A, Valacco MP, Cotignola J, Vazquez E, Gueron G. Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors. Antioxidants (Basel). 2022 Jan 31; 11(2). PMID: 35204174; PMCID: PMC8868058.
      Citations: 1     
    19. Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson SE, Chang Y, Wang X, Zhang Y, Vo JN, Kregel S, Simko SA, Delekta AD, Jaber M, Zheng H, Apel IJ, McMurry L, Su F, Wang R, Zelenka-Wang S, Sasmal S, Khare L, Mukherjee S, Abbineni C, Aithal K, Bhakta MS, Ghurye J, Cao X, Navone NM, Nesvizhskii AI, Mehra R, Vaishampayan U, Blanchette M, Wang Y, Samajdar S, Ramachandra M, Chinnaiyan AM. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022 01; 601(7893):434-439. PMID: 34937944; PMCID: PMC8770127.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    20. Kaochar S, Rusin A, Foley C, Rajapakshe K, Robertson M, Skapura D, Mason C, Berman De Ruiz K, Tyryshkin AM, Deng J, Shin JN, Fiskus W, Dong J, Huang S, Navone NM, Davis CM, Ehli EA, Coarfa C, Mitsiades N. Inhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocr Relat Cancer. 2021 11 24; 29(1):15-31. PMID: 34636746; PMCID: PMC8634153.
      Citations:    Fields:    Translation:HumansCells
    21. Labanca E, Yang J, Shepherd PDA, Wan X, Starbuck MW, Guerra LD, Anselmino N, Dong J, Chinnaiyan AM, Ravoori MK, Kundra V, Broom BM, Corn PG, Troncoso P, Logothethis CJ, Navone NM, Bizzotto JA, Gueron G. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol. 2022 04; 5(2):164-175. PMID: 34774481.
      Citations: 2     Fields:    Translation:HumansAnimals
    22. Labanca E, Anselmino N, Yang J, Shepherd PDA, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Araujo J, Logothetis C, Navone N, Bizzotto J, Sanchis P, Paez A, Antico-Arciuch V, Lage-Vickers S, Cotignola J, Vazquez E, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298. PMID: 34584218; PMCID: PMC8566229.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    23. Qiao Y, Choi JE, Tien JC, Simko SA, Rajendiran T, Vo JN, Delekta AD, Wang L, Xiao L, Hodge NB, Desai P, Mendoza S, Juckette K, Xu A, Soni T, Su F, Wang R, Cao X, Yu J, Kryczek I, Wang XM, Wang X, Siddiqui J, Wang Z, Fernandez-Salas E, Navone NM, Ellison SJ, Ding K, Eskelinen EL, Heath EI, Klionsky DJ, Zou W, Chinnaiyan AM, Bernard A. Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. Nat Cancer. 2021 09; 2:978-993. PMID: 34738088; PMCID: PMC8562569.
      Citations: 5     Translation:Humans
    24. Navone N, Cascardo F, Anselmino N, P?ez A, Labanca E, Sanchis P, Antico-Arciuch V, Gueron G, V?zquez E, Cotignola J. HO-1 Modulates Aerobic Glycolysis through LDH in Prostate Cancer Cells. Antioxidants (Basel). 2021 Jun 16; 10(6). PMID: 34208670; PMCID: PMC8235201.
      Citations: 3     
    25. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358. PMID: 33824525.
      Citations: 3     Fields:    Translation:Humans
    26. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264. PMID: 33753455; PMCID: PMC8172463.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    27. Labanca E, Mitrofanova A, Navone N, Lage-Vickers S, Bizzotto J, Valacco MP, Sanchis P, Nemirovsky S, Scorticati C, Mazza O, Vazquez E, Cotignola J, Gueron G. The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer. Commun Biol. 2021 01 22; 4(1):103. PMID: 33483585; PMCID: PMC7822895.
      Citations: 2     Translation:Humans
    28. Sablatura LK, Bircsak KM, Shepherd P, Queiroz K, Farach-Carson MC, Constantinou PE, Saleh A, Navone N, Harrington DA. Enhanced Viability for Ex vivo 3D Hydrogel Cultures of Patient-Derived Xenografts in a Perfused Microfluidic Platform. J Vis Exp. 2020 12 05; (166). PMID: 33346184; PMCID: PMC9250080.
      Citations: 1     Fields:    Translation:HumansAnimals
    29. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      Citations: 4     Fields:    Translation:Humans
    30. Labanca E, Navone N, Ortiz E, Sanchis P, Bizzotto J, Lage-Vickers S, Cotignola J, Vazquez E, Gueron G. Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer. Biomolecules. 2020 07 06; 10(7). PMID: 32640729; PMCID: PMC7407234.
      Citations: 2     Fields:    Translation:HumansCells
    31. Labanca E, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM, Vazquez ES. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer. 2020 07; 27(7):R255-R265. PMID: 32369771; PMCID: PMC7274538.
      Citations: 6     Fields:    Translation:HumansCells
    32. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946. PMID: 32576626; PMCID: PMC7501166.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    33. Labanca E, Meiss R, Navone N, Anselmino N, Bizzotto J, Sanchis P, Lage-Vickers S, Ortiz E, Valacco P, Paez A, Cotignola J, Vazquez E, Gueron G. HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression. Biomolecules. 2020 03 18; 10(3). PMID: 32197509; PMCID: PMC7175266.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    34. Starbuck M, Labanca E, Navone N, Zenclussen AC, Anselmino N, Cotignola J, Gueron G, Vazquez E. Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis. Antioxid Redox Signal. 2020 06 10; 32(17):1243-1258. PMID: 31861963; PMCID: PMC7232646.
      Citations: 7     Fields:    Translation:Animals
    35. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999. PMID: 31941830.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    36. Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, Sundaram SK, Li J, Wu KH, Chandrashekar DS, Peabody JO, Stricker H, Hwang C, Chitale DA, Williamson SR, Gupta NS, Navone NM, Rogers C, Menon M, Varambally S, Palanisamy N. Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia. 2019 10; 21(10):989-1002. PMID: 31446281; PMCID: PMC6713813.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    37. Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019 05 29; 11(494). PMID: 31142679; PMCID: PMC6999853.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    38. Piyarathna DWB, Balasubramanian A, Arnold JM, Lloyd SM, Karanam B, Castro P, Ittmann MM, Putluri N, Navone N, Jones JA, Yu W, Sandulache VC, Sikora AG, Michailidis G, Sreekumar A. ERR1 and PGC1a associated mitochondrial alterations correlate with pan-cancer disparity in African Americans. J Clin Invest. 2019 03 28; 129(6):2351-2356. PMID: 30920960; PMCID: PMC6546480.
      Citations: 11     Fields:    Translation:HumansCells
    39. Sinha KM, Bagheri-Yarmand R, Lahiri S, Lu Y, Zhang M, Amra S, Rizvi Y, Wan X, Navone N, Ozpolat B, Logothetis C, Gagel RF, Huard J. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene. 2019 06; 38(25):5038-5049. PMID: 30858546.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    40. Paindelli C, Navone N, Logothetis CJ, Friedl P, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials. 2019 03; 197:296-304. PMID: 30682644; PMCID: PMC7094882.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    41. Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019 04; 38(14):2451-2463. PMID: 30532030; PMCID: PMC6450769.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    42. Faria M, Shepherd P, Pan Y, Chatterjee SS, Navone N, Strom A, Gustafsson J?. The estrogen receptor variants ?2 and ?5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling. Oncotarget. 2018 Nov 20; 9(91):36273-36288. PMID: 30555629; PMCID: PMC6284737.
      Citations: 9     Fields:    
    43. Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E, Santer FR. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018 12; 78(16):1262-1282. PMID: 30073676.
      Citations: 33     Fields:    Translation:HumansAnimals
    44. Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, Navone N, De-Juan-Pardo EM, Logothetis CJ, Hutmacher DW, Friedl P. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med. 2018 08 01; 10(452). PMID: 30068572; PMCID: PMC6326183.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    45. Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S, S?ltmann H, Gr?llich C. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urol Oncol. 2018 08; 36(8):365.e15-365.e26. PMID: 29887238.
      Citations: 7     Fields:    Translation:Humans
    46. Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA. An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. Cancer Res. 2018 07 15; 78(14):3823-3833. PMID: 29769196; PMCID: PMC6381393.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    47. Chiarella P, Giudice J, Contin MD, Strazza A, Montagna DR, Labanca E, D Accorso N, Woloszynska-Read A, Navone N, Meiss RP, Gueron G, Anselmino N, Ortiz EG, Lage Vickers S, Paez AV, Leonardi D, Jaworski F, Manzano V, Cotignola J, Ruggiero R, Vazquez E. Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis. Cell Death Dis. 2018 02 02; 9(2):140. PMID: 29396431; PMCID: PMC5833805.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    48. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707. PMID: 29138344; PMCID: PMC5823274.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    49. Meiss RP, Ahmed A, Navone N, Jaworski FM, Gentilini LD, Gueron G, Ortiz EG, Berguer PM, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES. In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development. Clin Cancer Res. 2017 Sep 01; 23(17):5135-5148. PMID: 28512172.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    50. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017 02 21; 18(8):1970-1981. PMID: 28228262; PMCID: PMC5349188.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    51. Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017 02 23; 542(7642):484-488. PMID: 28166537; PMCID: PMC5448706.
      Citations: 84     Fields:    Translation:HumansCells
    52. Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Labanca E, Binaghi M, Salierno M, Cotignola JH, Woloszynska-Read A, Bruno L, Levi V, Navone N, Vazquez ES, Gueron G, Anselmino N, Mart? MA. Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Cell Death Dis. 2016 12 29; 7(12):e2570. PMID: 28032857; PMCID: PMC5261017.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    53. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Soghomonyan S, Alauddin MM, Flores LG, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Arap MA, Marchi? S. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12786-12791. PMID: 27791181; PMCID: PMC5111687.
      Citations: 21     Fields:    
    54. Kleb B, Zhang J, Tzelepi V, Navone NM, Tahir S, Marquez VE, Maity S, Aparicio A, Est?cio MR, Chung W, Jelinek J, Issa JP. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 2016 03 03; 11(3):184-93. PMID: 26890396; PMCID: PMC4854553.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    55. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res. 2016 04; 14(4):324-31. PMID: 26792867; PMCID: PMC4834259.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    56. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia. 2016 Jan; 18(1):1-9. PMID: 26806347; PMCID: PMC4735600.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    57. Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC. A 3D in?vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in?vivo tumor-stromal interactions. Biomaterials. 2016 Jan; 77:164-72. PMID: 26599623; PMCID: PMC4684431.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    58. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015 Oct 27; 6(33):34329-41. PMID: 26455377; PMCID: PMC4741456.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    59. Giudice J, Navone N, Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Zalazar F, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer Res. 2015 Nov; 13(11):1455-64. PMID: 26227317.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    60. Liu J, You P, Chen G, Fu X, Zeng X, Wang C, Huang Y, An L, Wan X, Navone N, Wu CL, McKeehan WL, Zhang Z, Zhong W, Wang F. Hyperactivated FRS2a-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene. 2016 Apr 07; 35(14):1750-9. PMID: 26096936; PMCID: PMC4781666.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    61. Salameh A, Lee AK, Efstathiou E, Staquicini FI, Dobroff AS, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Calin GA, Cavenee WK, Pasqualini R, Arap W, Card?-Vila M, Nunes DN, Marchi? S, Lima LA, Carraro DM, Brentani RR, Dias-Neto E. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8. PMID: 26080435; PMCID: PMC4500257.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    62. Pasqualini R, Millikan RE, Christianson DR, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W, Card?-Vila M. Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21. PMID: 25832466; PMCID: PMC4490036.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    63. Mandelin J, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W, Card?-Vila M. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81. PMID: 25762070; PMCID: PMC4378428.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    64. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122. PMID: 25186177; PMCID: PMC4407499.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    65. Gueron G, Giudice J, Valacco P, Paez A, Elguero B, Toscani M, Jaworski F, Leskow FC, Cotignola J, Marti M, Binaghi M, Navone N, Vazquez E. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget. 2014 Jun 30; 5(12):4087-102. PMID: 24961479; PMCID: PMC4147308.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    66. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47. PMID: 24847116; PMCID: PMC4135429.
      Citations: 47     Fields:    Translation:HumansAnimals
    67. Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC, Fong EL. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm. 2014 Jul 07; 11(7):2040-50. PMID: 24779589; PMCID: PMC4096229.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    68. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064; PMCID: PMC4009928.
      Citations: 136     Fields:    Translation:HumansAnimalsCells
    69. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. Heme oxygenase-1 (HO-1) expression in prostate cancer cells modulates the oxidative response in bone cells. PLoS One. 2013; 8(11):e80315. PMID: 24224047; PMCID: PMC3817116.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    70. Corn PG, Wang F, McKeehan WL, Navone N. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5856-66. PMID: 24052019; PMCID: PMC3926427.
      Citations: 51     Fields:    Translation:HumansCells
    71. Cotignola J, Leonardi DB, Shahabi A, Stern MC, Navone N, Scorticati C, De Siervi A, Mazza O, Vazquez E, Acu?a AD. Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013 Mar; 16(1):28-34. PMID: 23146971; PMCID: PMC3626169.
      Citations: 7     Fields:    Translation:Humans
    72. Gueron G, Giudice J, Toscani MA, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone N, De Siervi A, Vazquez E, Elguero B. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia. 2012 Nov; 14(11):1043-56. PMID: 23226098; PMCID: PMC3514752.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    73. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012 Oct; 41(4):1495-503. PMID: 22895552; PMCID: PMC3982713.
      Citations: 24     Fields:    Translation:HumansCells
    74. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47. PMID: 22457212; PMCID: PMC4977841.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    75. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012 Sep; 26(9):2114-23. PMID: 22425892; PMCID: PMC3381862.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    76. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One. 2012; 7(2):e31259. PMID: 22363599; PMCID: PMC3281954.
      Citations: 4     Fields:    Translation:HumansCells
    77. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of ?-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012 Feb 01; 18(3):726-36. PMID: 22298898; PMCID: PMC3271798.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    78. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W, Koumakpayi IH. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903. PMID: 22245216; PMCID: PMC4715215.
      Citations: 37     Fields:    Translation:AnimalsCells
    79. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840. PMID: 22194926; PMCID: PMC3237548.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    80. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77. PMID: 22156612; PMCID: PMC3923417.
      Citations: 70     Fields:    Translation:HumansAnimals
    81. Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. Effect of transforming growth factor beta (TGF-?) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2012 Mar; 50(3):695-703. PMID: 22173053; PMCID: PMC3278589.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    82. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed. 2012 Jun; 25(6):843-51. PMID: 22134886.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    83. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121. PMID: 22133722; PMCID: PMC3476478.
      Citations: 259     Fields:    Translation:HumansAnimalsCells
    84. Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E, Ferrando M. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. 2011 Dec; 14(4):467-79. PMID: 21833623.
      Citations: 36     Fields:    Translation:HumansAnimals
    85. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17; 19(5):664-78. PMID: 21575865; PMCID: PMC3113473.
      Citations: 214     Fields:    Translation:HumansAnimalsCells
    86. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011 Apr 15; 17(8):2328-38. PMID: 21343372; PMCID: PMC3078947.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    87. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 01; 71(8):846-56. PMID: 21456067; PMCID: PMC3883511.
      Citations: 39     Fields:    Translation:HumansAnimals
    88. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010 Nov 02; 10:599. PMID: 21044312; PMCID: PMC2988752.
      Citations: 19     Fields:    Translation:Humans
    89. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate. 2010 Nov 01; 70(15):1709-15. PMID: 20564322; PMCID: PMC4977846.
      Citations: 64     Fields:    Translation:AnimalsCells
    90. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011 Jan; 42(1):11-7. PMID: 21040948; PMCID: PMC5972369.
      Citations: 39     Fields:    Translation:HumansAnimals
    91. Navone NM. P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells. Cell Cycle. 2010 Aug 01; 9(15):2935. PMID: 20703082.
      Citations: 2     Fields:    Translation:HumansAnimals
    92. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010 May; 221(1):68-76. PMID: 20191612; PMCID: PMC2936767.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    93. Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V. Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model. PLoS One. 2010 Mar 29; 5(3):e9854. PMID: 20360964; PMCID: PMC2847943.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    94. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res. 2009 Nov; 7(11):1745-55. PMID: 19903769.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    95. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    96. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; PMCID: PMC2562877.
      Citations: 9     Fields:    Translation:Humans
    97. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    98. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. PMID: 18213636; PMCID: PMC3681409.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    99. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602. PMID: 18347159.
      Citations: 21     Fields:    Translation:HumansAnimals
    100. Meiss R, Casas G, Mazza O, Calvo JC, Navone N, Vazquez E, Sacca P. Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. Br J Cancer. 2007 Dec 17; 97(12):1683-9. PMID: 18026199; PMCID: PMC2360287.
      Citations: 55     Fields:    Translation:HumansCells
    101. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603. PMID: 17700537.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    102. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8. PMID: 17638862; PMCID: PMC2000837.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    103. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84. PMID: 17634423; PMCID: PMC2000833.
      Citations: 19     Fields:    Translation:HumansCells
    104. Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM. In vivo imaging of prostate cancer involving bone in a mouse model. Prostate. 2007 Jan 01; 67(1):50-60. PMID: 17031813.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    105. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006 Nov 15; 66(22):10919-28. PMID: 17108129.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    106. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):203-11. PMID: 16081281.
      Citations: 3     Fields:    Translation:AnimalsCells
    107. Navone NM, Fizazi K. [Preclinical models of prostate cancer]. Bull Cancer. 2005 Feb; 92(2):129-41. PMID: 15749642.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    108. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004 Sep-Oct; 24(5A):2897-903. PMID: 15517894.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    109. Navone NM, Olive M, Troncoso P. Isolation and culture of prostate cancer cell lines. Methods Mol Med. 2004; 88:121-32. PMID: 14634223.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    110. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003 Jul; 9(7):2587-97. PMID: 12855635.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    111. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):785-8. PMID: 12548576.
      Citations: 3     Fields:    Translation:Humans
    112. Martinez LA, Yang J, Vazquez ES, Olive M, Hsieh JT, Logothetis CJ, Navone NM, Rodriguez-Vargas Mdel C. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002 Aug; 23(8):1289-96. PMID: 12151346.
      Citations: 26     Fields:    Translation:HumansCells
    113. Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002 Jun 01; 51(4):225-30. PMID: 11987150.
      Citations: 3     Fields:    Translation:HumansCells
    114. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Troncoso P, Navone NM, Ordo?ez NG. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81. PMID: 11895908.
      Citations: 19     Fields:    Translation:HumansAnimals
    115. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett. 2002 Feb 08; 176(1):57-63. PMID: 11790454.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    116. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002 Apr 12; 277(15):12622-31. PMID: 11812785.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    117. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol. 2001 Oct; 48(4):319-26. PMID: 11710633.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    118. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9. PMID: 11454720.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    119. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology. 2000 Jul; 141(7):2548-56. PMID: 10875257.
      Citations: 27     Fields:    Translation:HumansCells
    120. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000 Jun; 6(6):703-6. PMID: 10835690.
      Citations: 154     Fields:    Translation:HumansAnimalsCells
    121. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7. PMID: 10741751.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    122. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol. 1999 Dec; 162(6):2192-9. PMID: 10569618.
      Citations: 22     Fields:    Translation:HumansCells
    123. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999 Jan; 161(1):304-8. PMID: 10037428.
      Citations: 21     Fields:    Translation:Humans
    124. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet. 1998 Oct 15; 106(2):105-9. PMID: 9797773.
      Citations: 1     Fields:    Translation:HumansCells
    125. Pisters LL, Troncoso P, Navone N. Prolonged survival with metastatic prostate cancer to bone. J Urol. 1998 Jun; 159(6):2100. PMID: 9598540.
      Citations:    Fields:    Translation:Humans
    126. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. Int J Oncol. 1998 Mar; 12(3):589-95. PMID: 9472097.
      Citations: 3     Fields:    Translation:HumansCells
    127. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998-1999; 17(4):361-71. PMID: 10453280.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    128. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500. PMID: 9815652.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    129. Polo CF, Buzaleh AM, Vazquez ES, Afonso SG, Navone NM, Batlle AM. Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Gen Pharmacol. 1997 Aug; 29(2):207-10. PMID: 9251900.
      Citations: 3     Fields:    Translation:Animals
    130. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74. PMID: 8996359.
      Citations: 18     Fields:    Translation:Humans
    131. Polo CF, Afonso SG, Navone NM, Rossetti MV, del C Batlle AM. Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Ecotoxicol Environ Saf. 1995 Dec; 32(3):267-72. PMID: 8964254.
      Citations: 2     Fields:    Translation:HumansCells
    132. Chen Y, Navone NM, Conti CJ. Expression of cyclin DI in human prostate cancer cell lines. Urol Oncol. 1995 May-Jun; 1(3):101-8. PMID: 21224101.
      Citations: 2     Fields:    
    133. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology. 1995 Mar; 45(3):470-5. PMID: 7879337.
      Citations: 9     Fields:    Translation:HumansCells
    134. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993 Oct 20; 85(20):1657-69. PMID: 7692074.
      Citations: 74     Fields:    Translation:HumansCells
    135. Navone NM, Polo CF, Batlle AM, V?zquez ES. Rhodanese and ALA-S in mammary tumor and liver from normal and tumor-bearing mice. Comp Biochem Physiol B. 1992 May; 102(1):83-5. PMID: 1526138.
      Citations: 1     Fields:    Translation:AnimalsCells
    136. Navone NM, Afonso SG, Polo CF, Batlle AM. Uroporphyrinogen decarboxylase from mouse mammary carcinoma and liver of normal and tumor-bearing mouse. Comp Biochem Physiol B. 1992 May; 102(1):87-92. PMID: 1526139.
      Citations:    Fields:    Translation:Animals
    137. Conti CJ, Bianchi AB, Navone NM, Ruggieri BA, Caamano J, Goodrow T, Klein-Szanto AJ. Tumor suppressor genes in squamous cell carcinoma. Prog Clin Biol Res. 1992; 376:85-101. PMID: 1528931.
      Citations:    Fields:    Translation:HumansAnimals
    138. Navone NM, Bianchi AB, Angel JM, Conti CJ. A novel polymorphism near the mouse Int-2 locus. Mamm Genome. 1992; 3(5):296-7. PMID: 1638089.
      Citations: 2     Fields:    Translation:AnimalsCells
    139. Bianchi AB, Navone NM, Aldaz CM, Conti CJ. Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis. Proc Natl Acad Sci U S A. 1991 Sep 01; 88(17):7590-4. PMID: 1909026; PMCID: PMC52347.
      Citations: 9     Fields:    Translation:AnimalsCells
    140. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol. 1991 Feb; 138(2):279-84. PMID: 1992758; PMCID: PMC1886207.
      Citations: 12     Fields:    Translation:AnimalsCells
    141. Navone NM, Buzaleh AM, Polo CF, Afonso SG, Batlle AM, V?zquez ES. The effect of griseofulvin on the heme pathway--II. An exhaustive analysis during short and long-term challenge. Gen Pharmacol. 1991; 22(6):1179-83. PMID: 1810812.
      Citations:    Fields:    Translation:AnimalsCells
    142. Navone NM, Polo CF, Frisardi AL, Batlle AM. Mouse mammary carcinoma porphobilinogenase and hydroxymethylbilane synthetase. Comp Biochem Physiol B. 1991; 98(1):67-71. PMID: 2060282.
      Citations: 5     Fields:    Translation:Animals
    143. Afonso SG, Polo CF, Navone NM, Vazquez ES, Buzaleh AM, Schoua E, Batlle AM. In vivo prevention and reversal by the antimitotic colchicine and other related compounds of some porphyrinogenic drug action on heme pathway. Gen Pharmacol. 1990; 21(4):423-6. PMID: 2379798.
      Citations:    Fields:    Translation:Animals
    144. Polo CF, Frisardi AL, Andrade NE, Battle AM, Navone NM. Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels. Int J Biochem. 1990; 22(12):1407-11. PMID: 2276414.
      Citations: 21     Fields:    Translation:Humans
    145. Navone NM, Polo CF, Frisardi AL, Batlle AM. Mouse mammary carcinoma delta-aminolevulinate dehydratase. Comp Biochem Physiol B. 1990; 96(4):729-31. PMID: 2225774.
      Citations:    Fields:    Translation:Animals
    146. Navone NM, Polo CF, Dinger RM, Batlle AM. Heme regulation in mouse mammary carcinoma and liver of tumor bearing mice--I. Effect of allyl-isopropylacetamide and veronal on delta-aminolevulinate synthetase, cytochrome P-450 and cytochrome oxidase. Int J Biochem. 1990; 22(9):1005-8. PMID: 2178097.
      Citations:    Fields:    Translation:Animals
    147. Vazquez E, Afonso S, Buzaleh AM, Navone N, Polo C, Schoua E, Batlle A. The effect of griseofulvin on the heme pathway. Studies on tissue explant cultures. Toxicology. 1987 Oct 12; 46(1):73-82. PMID: 3660422.
      Citations:    Fields:    Translation:Animals
    148. Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678]. Cancer Cell. 23:557.
    149. Expression of cyclin DI in human prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations. 1:101-108.
    150. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia (United States). 18:1-9.
    151. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials. 77:164-172.
    152. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 99:10941.
    153. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Molecular Cancer Research. 14:324-331.
    154. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene.
    155. Erratum. Science Translational Medicine. 7.
    156. Erratum. Nature Medicine. 6:939.
    157. Targeted molecular-genetic imaging and liganddirected therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:12786-12791.
    158. Porphyrin bioasynthesis in human breast cancer. Preliminary mimetic in vitro studies. Medical Science Research. 16:61-62.
    159. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 1-10.
    160. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 6:34329-34341.
    161. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Molecular Pharmaceutics. 11:2040-2050.
    162. About phototoxicity of griseofulvin. Possible mechanisms of action using cultures of tissular explants. Revista Argentina de Dermatologia. 68.
    NAVONE's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (602)
    Co-Authors (97)
    Similar People (60)
    Same Department Expand Description